Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Xilio Therapeutics (XLO)

Annual Return

Over the past 3 years, XLO has had an average annual return of -42.00%, underperforming the benchmark SPY, which returned +22.45% annual.

Since Oct 22, 2021, XLO has had an average annual return of -51.21%, underperforming the benchmark SPY, which returned +13.18% annual.

202620252024202320222021
-9.00%-33.00%+73.55%-79.54%-83.19%+0%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026-7.00%-11.29%+13.64%-5.60%+6.78%-3.70%-9.00%
2025-26.13%+28.34%-19.96%+5.74%+39.67%-36.47%-4.71%+8.15%+20.32%-5.50%-4.82%-15.61%-33.00%
2024+18.02%+9.11%+52.37%-3.70%+3.85%-12.30%+0.34%-9.76%-8.21%+61.38%-14.23%-12.33%+73.55%
2023+35.69%-1.10%-12.19%+4.14%-7.61%-14.06%+9.16%+0.34%-26.48%+3.79%-58.88%-38.90%-79.54%
2022-14.94%-13.44%-39.98%-50.08%-15.00%-2.67%-0.66%-22.78%+29.93%-19.57%+3.42%+11.10%-83.19%
2021+4.94%-5.66%+1.01%+0%

Drawdown analysis of Xilio Therapeutics (XLO)

The maximum drawdown for the XLO was -98.01%, occurring on Dec 20, 2023. This drawdown has not yet recovered.

The current XLO drawdown is -97.68%.

Since Oct 22, 2021 XLO has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 1 time
  • 10% or more: 2 times
DepthStartTo BottomBottomTo RecoverEndTotal
-98.01%Nov 16, 2021526Dec 20, 2023OngoingOngoingOngoing
-15.07%Nov 2, 20211Nov 3, 20211Nov 4, 20212
-7.67%Nov 4, 20211Nov 5, 20211Nov 8, 20212
-6.89%Nov 8, 20214Nov 12, 20212Nov 16, 20216
-2.19%Oct 26, 20211Oct 27, 20212Oct 29, 20213